Please assess the completion status of the following clinical trial:

Trial Title: BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged 18 years and older or postmenopausal women aged 55 years and older or women aged 18 years and older without childbearing potential based on surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy~* Clinical diagnosis of CHF (chronic heart failure), either ischemic or non-ischemic, NYHA (New York Heart Association) class II - III, treated with evidenced-based therapy for CHF, e.g. beta-blockers and ACE (angiotensin-converting enzyme) inhibitors or ARB (angiotensin receptor blocker) as well as diuretics, unless contraindicated or not tolerated~* Known kidney damage for \>/= 3 months, as defined by structural or functional abnormalities of the kidney, and~  * Part A: 60 mL/min/1.73 m\*2 \</= eGFR (estimated Glomerular Filtration Rate) \< 90 mL/min/1.73 m\*2 (MDRD, Modification of Diet in Renal Disease) at the screening visit~ * Part B: 30 mL/min/1.73 m\*2 \</= eGFR \<= 60 mL/min/1.73 m\*2 (MDRD) at the screening visit~* Serum potassium \</= 4.8 mmol/L at the screening visit~* Systolic blood pressure \>/= 90 mmHg without signs or symptoms of hypotension at the screening visit~Exclusion Criteria:~* Known hypersensitivity to the study drug (active substance or excipients) or spironolactone and respective excipients (Part B only)~* Subjects with anuria, acute renal failure, or Addison's disease~* Acute coronary syndrome or unstable coronary artery disease within 30 days prior to randomization~* Valvular heart disease requiring surgical intervention during the course of the study~* History of hospitalization for hyperkalemia or acute renal failure induced by previous aldosterone antagonist treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: EXPERIMENTAL): None
- Arm 4 (Type: EXPERIMENTAL): None
- Arm 5 (Type: PLACEBO_COMPARATOR): None
- Arm 6 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).